BridgeBio (BBIO) Q4 FY25 earnings call

BridgeBio Pharma reported a transformative Q4 FY25, marked by strong commercial execution of Attruby and positive Phase III readouts for three pipeline assets: encaleret, BBP-418, and infigratinib. The company is transitioning from a cash-consumptive model to a cash-generating one by 2028, driven by its diversified late-stage portfolio. Despite market volatility related to tafamidis IP, management remains confident in Attruby's differentiated clinical profile and the intrinsic value of its pipeline.